Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 285 shares of the company stock, valued at approximately $ 49,000.
Several other large investors have also recently modified their holdings of the company. Capital Investment Counsel Inc increased its position in Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company stock worth $ 1,334,000 after buying an additional 59 shares during the period. Beaton Management Co. Inc. increased its position in Johnson & Johnson by 0.3% in the fourth quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company stock worth $ 3,806,000 after buying an additional 60 shares during the period. Iron Horse Wealth Management LLC increased its position in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after buying an additional 61 shares during the period. Jag Capital Management LLC increased its position in Johnson & Johnson by 1.4% in the fourth quarter. Jag Capital Management LLC now owns 4,515 shares of the company stock worth $ 772,000 after buying an additional 61 shares during the period. Finally, Benchmark Financial Wealth Advisors LLC increased its position in Johnson & Johnson by 3.7% in the fourth quarter. Benchmark Financial Wealth Advisors LLC now owns 1,774 shares of the company stock worth $ 303,000 after buying an additional 63 shares during the period. 68.78% of the stock is owned by hedge funds and other institutional investors.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total transaction of $ 1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $ 2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 29,699 shares of the firm’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company stock, valued at $ 14,729,724.88. The disclosure for this sale can be found here. Insiders have sold a total of 101,842 shares of company stock valued at $ 18,069,079 over the last 90 days. Corporate insiders own 0.35% of the company stock.
NYSE: JNJ opened at $ 168.19 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 1-year low of $ 155.72 and a 1-year high of $ 186.69. The firm has a market capitalization of $ 442.58 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 3.41 and a beta of 0.66. The stock has a fifty day simple moving average of $ 178.83 and a 200 day simple moving average of $ 172.64.
Johnson & Johnson (NYSE: JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same quarter last year, the company posted $ 2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were given a $ 1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
A number of brokerages have recently commented on JNJ. Bank of America began coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Morgan Stanley lowered their price target on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price target for the company from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Raymond James raised their price target on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, Credit Suisse Group raised their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $ 190.50.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading:
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.